Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
ARTS-011 is a promising oral Tyk2 inhibitor with an acceptable safety profile and potential for once-daily dosing. These results support further clinical development of ARTS-011 in patients with inflammatory and autoimmune diseases.
Authors
- Jingxuan Wu (ORCID: https://orcid.org/0009-0006-3268-5878)
- Xipan Liu
- Yaoyu Chen (ORCID: https://orcid.org/0000-0003-4587-0539)
- Jingcheng Chen (ORCID: https://orcid.org/0000-0002-1199-9599)
- Tao Ji (ORCID: https://orcid.org/0000-0003-4522-8888)
- RUIHUA DONG
- Cong Zhu (ORCID: https://orcid.org/0009-0000-6077-4647)
- Xiaobin Zhang
- Yan Wang
- Wenheng Liang
- Yuqin Song
- Zhen Liu
- Jing Yang
- Zhili Jin
- Jiangshuo Li
- Qing Sheng
- Jiaqi Liang
Institutions
- Capital Medical University (CN)
- Beijing Friendship Hospital (CN)
- Guangzhou Electronic Technology (China) (CN)
- Cytori Therapeutics (United States) (US)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1111/bph.70338
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00